Clinical Trial Update: First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating first-line apatinib combined with tislelizumab and chemotherapy for advanced gastric adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• Apatinib (apatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Renmin Hospital of Wuhan University | Conditions: Advanced Gastric Adenocarcinoma | Phase 2 | Status: COMPLETED